It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hereditary degeneration of photoreceptors has been linked to over-activation of Ca2+-permeable channels, excessive Ca2+-influx, and downstream activation of Ca2+-dependent calpain-type proteases. Unfortunately, after more than 20 years of pertinent research, unequivocal evidence proving significant and reproducible photoreceptor protection with Ca2+-channel blockers is still lacking. Here, we show that both D- and L-cis enantiomers of the anti-hypertensive drug diltiazem were very effective at blocking photoreceptor Ca2+-influx, most probably by blocking the pore of Ca2+-permeable channels. Yet, unexpectedly, this block neither reduced the activity of calpain-type proteases, nor did it result in photoreceptor protection. Remarkably, application of the L-cis enantiomer of diltiazem even led to a strong increase in photoreceptor cell death. These findings shed doubt on the previously proposed links between Ca2+ and retinal degeneration and are highly relevant for future therapy development as they may serve to refocus research efforts towards alternative, Ca2+-independent degenerative mechanisms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Tübingen, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
2 University Hospital Jena, Friedrich Schiller University Jena, Institute of Physiology II, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)
3 University of Tübingen, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Werner Reichardt Centre for Integrative Neuroscience (CIN), Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
4 University Hospital Jena, Friedrich Schiller University Jena, Institute of Physiology II, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794); University Hospital Jena, Friedrich Schiller University Jena, Biomolecular Photonics Group, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)
5 University Hospital Jena, Friedrich Schiller University Jena, Biomolecular Photonics Group, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)
6 University of Tübingen, Werner Reichardt Centre for Integrative Neuroscience (CIN), Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
7 BIOLOG Life Science Institute GmbH & Co KG, Bremen, Germany (GRID:grid.431919.7) (ISNI:0000 0004 0552 8015)